S-ClassAbout S-Class
F
FHTXAI Stock Diagnostic Report
Foghorn Therapeutics GAAP EPS of -$0.10 beats by $0.14, revenue of $16.1M beats by $8.17M
Foghorn Therapeutics reported strong performance with earnings per share (EPS) and revenue exceeding expectations.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$4.88Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support4.41
Near-Term Resistance6.33
02
FUNDAMENTALS
Financial & Fundamental Analysis
Foghorn Therapeutics reported a GAAP EPS of -$0.10, exceeding the consensus estimate of $0.14, and achieved revenue of $16.1M, surpassing expectations by $8.17M, resulting in a financial surprise.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $4.88 is positioned between the 20-day low of $4.41 and the high of $6.33, and the moving averages are not aligned.
Support4.41
Resistance6.33
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
An earnings surprise occurred, but trading volume was low at 59% of the 20-day average, which may result in a temporary relief rally rather than strong buying inflow.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-06)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.